Pack Content Directory Botswana

Monday, 10 September 2012

Femoston 1 / 10mg and 2 / 10mg

femoston

1/10 mg

femoston

2/10 mg

film-coated tablets

estradiol/dydrogesterone

What you should know about Femoston

Please read this leaflet before you take your medicine, and keep it safe because you may want to read it again. If you have any questions or are not sure about anything, ask your doctor or a pharmacist.

What is in Femoston?

Femoston belongs to a group of medicines known as Hormone Replacement Therapy or HRT.

Each pack of Femoston tablets contains two different types of tablets.

Femoston 1/10: the white tablets contain 1 mg of estradiol (as hemihydrate) and the grey tablets contain 1 mg of estradiol (as hemihydrate) and 10 mg of dydrogesterone.

Femoston 2/10: the brick-red tablets contain 2 mg of estradiol (as hemihydrate) and the yellow tablets contain 2 mg of estradiol (as hemihydrate) and 10 mg of dydrogesterone.

All of the tablets can be recognised by the following markings: 'a letter S above a triangle’ on one side and ‘379’ on the other side.

The estradiol in the tablets is made from plant materials. The tablets also contain lactose, hypromellose, maize starch, colloidal anhydrous silica, magnesium stearate and titanium dioxide (E171).

In addition, the white tablets contain macrogol 400; the grey tablets contain macrogol 3350, iron oxides (E172), talc and polyvinylalcohol; the yellow tablets and the red tablets contain macrogol 400, talc and iron oxides (E172).

Femoston is available as a three month pack (84 tablets) containing 3 strips of 28 tablets each or in a one month pack (28 tablets) containing one strip of 28 tablets. The strips are marked with the days of the week to help you remember to take your tablets. The arrows marked 1 and 2 show you which order to take the tablets in. All pack sizes may not be marketed.

The marketing authorisation holder is

Solvay Healthcare Limited

Southampton

SO18 3JD

Femoston is made by

Solvay Biologicals BV

8121 AA Olst

The Netherlands

What is Femoston for?

Femoston 1/10 and 2/10 are continuous sequential HRTs for peri and postmenopausal women, used to treat the symptoms of the menopause (change of life). These symptoms vary from woman to woman, and can include hot flushes, night sweats, sleeping difficulties, dryness of the vagina and urinary problems.

Femoston may also be used to prevent osteoporosis (thinning of the bones) in women who are at an increased risk of fractures but who are unable to take other medicines for osteoporosis prevention or if these have proved to be ineffective. Your doctor should discuss all the available options with you. Osteoporosis can accelerate after the menopause as estrogen levels fall. If your doctor has prescribed Femoston for treatment of menopausal symptoms, you will not need to take another medicine to prevent osteoporosis whilst you are taking Femoston. Femoston is suitable for peri and postmenopausal women who may or may not still be having their periods and women switching from standard (cyclic or sequential) HRT on the advice of their doctor.

Femoston 1/10 and Femoston 2/10 are not contraceptives. If you need contraception you should use a non-hormonal method.

How does Femoston work?

Femoston contains estradiol and dydrogesterone. These hormones replace the estradiol and progesterone you produce in your ovaries from puberty until the menopause. Your body’s natural estrogen is also called estradiol. Dydrogesterone is a manufactured form of progesterone which is very similar to a woman’s own progesterone.

Estradiol replaces your body’s natural estrogen, controlling your menopausal symptoms and giving protection against osteoporosis. Women who still have a womb should normally take some form of progesterone (a progestagen), because estrogen alone can cause problems due to a build up of the womb lining. Taking dydrogesterone for part of each monthly cycle (as in Femoston) helps prevent a build up of the womb lining by inducing a regular monthly bleed (see ‘Endometrial cancer’).

Before taking Femoston

Before you take your medicine, you should make sure that it is safe for you to do so. If you answer yes to any of the following questions, do not take Femoston:

Are you allergic to any of the tablet ingredients?

Do you have, have you had, or does your doctor think you might have, breast cancer?

Have you had or does your doctor think that you might have a tumour which is made worse by estrogens (e.g., endometrial cancer)?

Have you had or does your doctor think that you might have a tumour which is made worse by progestagens (e.g. meningioma)?

Do you have undiagnosed vaginal bleeding that is not associated with your period?

Do you have or are you being treated for a blood clot in an artery or in a vein in your leg or any
where else (a deep vein thrombosis), or a blood clot that has travelled to your lung or other parts of your body (an embolus)? Have you had one of these conditions in the past?

Do you have angina, or have you ever had a heart attack or stroke?

Do you have acute liver disease or has your liver function not returned to normal after a liver disease?

Has your doctor told you that you have porphyria (a metabolic disorder)?

Are you pregnant or do you think that you might be pregnant?

This product contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.

If any of the following apply to you, you should check with your doctor before you start taking Femoston:

you have or have had serious liver disease; or

you have irregular or unusually heavy periods; or

you have or have had endometrial hyperplasia.

Medical check-ups

Before you start taking HRT, your doctor should ask about your own and your family’s medical history.

Your doctor may decide to examine your breasts and/or your abdomen, and may do an internal examination - but only if these examinations are necessary for you, or if you have any special concerns.

Once you’ve started on HRT, you should see your doctor for regular check-ups (at least once a year).

At these check-ups, your doctor may discuss with you the benefits and risks of continuing to take HRT.

Be sure to:

go for regular breast screening and cervical smear tests

regularly check your breasts for any changes such as dimpling of the skin, changes in the nipple,
or any lumps you can see or feel.

If you have (or had in the past, or are at risk of getting) any of the following conditions, your doctor may want
to see you more often for check-ups:

fibroids or endometriosis

blood clots in the legs or lungs

tumours related to estrogens

high blood pressure

liver complaints

sugar diabetes

gall stones

migraine or severe headache

systemic lupus erythematosus (SLE) (a disease which affects the skin and major organs)

epilepsy (fits)

asthma

otosclerosis (a type of deafness)

Safety of HRT

As well as benefits, HRT has some risks which you need to consider when you’re deciding whether to take it, or whether to carry on taking it.

Effects on your heart or circulation

Heart disease

HRT is not recommended for women who have heart disease, or have had heart disease recently. If you have had heart disease, talk to your doctor to see if you should take HRT.

HRT will not help to prevent heart disease.

Studies with one type of HRT (containing conjugated estrogen plus the progestagen MPA), have shown that women may be slightly more likely to get heart disease during the first year of taking the medication. For other types of HRT, the risk is likely to be similar, although this is not yet certain.

If you get:

a pain in your chest that spreads to your arm or neck

See a doctor as soon as possible and do not take any more HRT until your doctor says you can. This pain could be a sign of heart disease.

Stroke

Recent research suggests that HRT slightly increases the risk of having a stroke. Other things that can increase the risk of stroke include:

getting older

high blood pressure

smoking

drinking too much alcohol

an irregular heartbeat

If you are worried about any of these things,
or if you have had a stroke in the past, talk to your doctor to see if you should take HRT.

Compare

Looking at women in their 50s who are not taking HRT - on average, over a 5-year period, 3 in 1000 would be expected to have a stroke.

For women in their 50s who are taking HRT, the figure would be 4 in 1000.

Looking at women in their 60s who are not taking HRT - on average, over a 5-year period, 11 in 1000 would be expected to have a stroke.

For women in their 60s who are taking HRT, the figure would be 15 in 1000.

If you get:

unexplained migraine-type headaches, with or without disturbed vision

See a doctor as soon as possible and do not take any more HRT until your doctor says you can. These headaches may be an early warning sign of a stroke.

Blood clots

HRT may increase the risk of blood clots in the veins (also called deep vein thrombosis, or DVT), especially during the first year of taking it.

These blood clots are not always serious, but if one travels to the lungs, it can cause chest pain,
breathlessness, collapse or even death.

This condition is called pulmonary embolism, or PE.

DVT and PE are examples of a condition called venous thromboembolism, or VTE.

You are more likely to get a blood clot:

if you are seriously overweight

if you have had a blood clot before

if any of your close family have had blood clots

if you have had one or more miscarriages

if you have any blood clotting problem that needs treatment with a medicine such as warfarin

if you’re off your feet for a long time because of major surgery, injury or illness

if you have a rare condition called SLE

If any of these things apply to you
, talk to your doctor to see if you should take HRT.

Compare

Looking at women in their 50s who are not taking HRT - on average, over a 5-year period, 3 in 1000 would be expected to get a blood clot.

For women in their 50s who are taking HRT, the figure would be 7 in 1000.

Looking at women in their 60s who are not taking HRT - on average, over a 5-year period, 8 in 1000 would be expected to get a blood clot.

For women in their 60s who are taking HRT, the figure would be 17 in 1000.

If you get:

painful swelling in your leg

sudden chest pain

difficulty breathing

See a doctor as soon as possible and do not take any more HRT until your doctor says you
can. These may be signs of a blood clot.

If you’re going to have surgery,
make sure your doctor knows about it. You may need to stop taking HRT about 4 to 6 weeks before the operation, to reduce the risk of a blood clot. Your doctor will tell you when you can start taking HRT again.

Effects on your risk of developing cancer

Breast cancer

Women who have breast cancer, or have had breast cancer in the past, should not take HRT.

Taking HRT slightly increases the risk of breast cancer; so does having a later menopause. The risk for a post-menopausal woman taking estrogen-only HRT for 5 years is about the same as for a woman of the same age who’s still having periods over that time and not taking HRT. The risk for a woman who is taking estrogen plus progestagen HRT is higher than for estrogen-only HRT (but estrogen plus progestagen HRT is beneficial for the endometrium, see ‘Endometrial cancer’ below).

For all kinds of HRT, the extra risk of breast cancer goes up the longer you take it, but returns to normal
within about 5 years after stopping.

Your risk of breast cancer is also higher:

if you have a close relative (mother, sister or grandmother) who has had breast cancer

if you are seriously overweight

Compare

Looking at women aged 50 who are not taking HRT - on average, 32 in 1000 will be diagnosed with breast cancer by the time they reach the age of 65.

For women who start taking estrogen-only HRT at age 50 and take it for 5 years, the figure will be 33 and 34 in 1000 (ie an extra 1-2 cases).

If they take estrogen-only HRT for 10 years, the figure will be 37 in 1000 (an extra 5 cases).

For women who start taking estrogen plus progestagen HRT at age 50 and take it for 5 years, the figure will be 38 in 1000 (ie an extra 6 cases).

If they take estrogen plus progestagen HRT for 10 years, the figure will be 51 in 1000 (ie an extra 19
cases).

If you notice
any changes in your breast, such as:

dimpling of the skin

changes in the nipple

any lumps you can see or feel

Make an appointment to see your doctor as soon as possible.

Endometrial cancer (cancer of the lining of the womb)

Taking estrogen-only HRT for a long time can increase the risk of cancer of the lining of the womb (the endometrium). Taking a progestagen as well as the estrogen helps to lower the extra risk.

If you still have your womb, your doctor may prescribe a progestagen as well as estrogen.

If so, these may be prescribed separately, or as a combined HRT product.

If you have had your womb removed (a hysterectomy), your doctor will discuss with you whether you can safely take estrogen without a progestagen.

If you’ve had your womb removed because of endometriosis, any endometrium left in your body may be at risk. So your doctor may prescribe HRT that includes a progestagen as well as an estrogen.

Your product, Femoston contains a progestagen

Compare

Looking at women who still have a uterus and who are not taking HRT – on average 5 in 1000 will be
diagnosed with endometrial cancer between the ages of 50 and 65.

For women who take estrogen-only HRT the number will be 2 to 12 times higher, depending on the dose and how long you take it.

The addition of a progestagen to estrogen-only HRT substantially reduces the risk of endometrial cancer.

If you get breakthrough bleeding or spotting, it’s usually nothing to worry about, especially during the first few months of taking HRT.

But if the bleeding or spotting:

carries on for more than the first few months

starts after you’ve been on HRT for a while

carries on even after you’ve stopped taking HRT

Make an appointment to see your doctor. It could be a sign that your endometrium has become thicker.

Ovarian cancer

Ovarian cancer (cancer of the ovaries) is very rare, but it is serious. It can be difficult to diagnose, because
there are often no obvious signs of the disease. Some studies have indicated that taking estrogen-only HRT for more than 5 years may increase the risk of ovarian cancer. It is not yet known whether other kinds of HRT increase the risk in the same way.

Are you taking any of these other medicines?

If you are taking anticonvulsants (eg. phenobarbital, phenytoin, carbamezapine), anti-infectives (e.g. rifampicin, rifabutin, nevirapine, efavirenz), ritonavir, nelfinavir or herbal preparations containing St John’s wort (Hypericum perforatum), talk to your doctor or a pharmacist. These other medicines may stop Femoston working properly.

How to take Femoston

Generally your doctor will start you on Femoston 1/10 mg. Your doctor will aim to give you the lowest dose for the shortest time to treat your symptoms. The dose can then be increased, by your doctor, if necessary. Take one tablet every day, without a break between packs. Swallow the tablet with water, with or without food.

If you are having regular periods you should start taking Femoston within five days of the start of bleeding. If you are not having regular periods and are not taking any other HRT preparations, or you are switching from a combined continuous HRT product, you can start taking Femoston on any convenient day.

If you are currently using a ‘cyclic’ or ‘sequential’ HRT preparation (which involves taking an estrogen tablet
or patch for part of the month, followed by both estrogen and progestagen tablet or patch for up to 14 days) start taking Femoston the day after you finish the pack i.e. at the end of the progestagen phase. If you forget to take a tablet, take the next one as soon as you remember. If it is more than 12 hours since you took the last one, take the next dose without taking the forgotten tablet. If you miss a tablet, it is more likely that you will have irregular bleeds.

Overdose

If you (or someone else, e.g. a child) take too many Femoston tablets, they are unlikely to do any harm. Nausea, vomiting, sleepiness and dizziness may occur. No treatment is necessary, but if you are worried, contact your doctor for advice.

Possible side effects

Some women may have side effects when taking Femoston, but they usually disappear after the first few months. In the list of possible side effects given below, we give an indication of how likely it is that you will get these side effects: ‘common’ means less than one in ten patients may experience this side effect; ‘uncommon’ means less than one in a hundred; ‘rarely’ means less than one in a thousand; and ‘very rarely’ means less than one in ten thousand patients.

Infections: Symptoms of cystitis; thrush; (uncommon)

Tumours: Breast cancer; fibroids get bigger; (uncommon)

Blood changes: Anaemia (iron deficiency); (very rare)

Mental problems: Depression; change in sex drive; nervousness; (uncommon)

Nervous system: Headache; migraine; (common). Dizziness; (uncommon). Chorea (muscle twitches); (very rare)

Eye changes: Intolerance to contact lenses; change in the surface of the eye; (rare)

Heart: Heart attack; (very rare)

Blood vessels: High blood pressure; peripheral vascular disease; varicose veins; venous thromboembolism (blood clots in the legs, pelvis or lungs); (uncommon). Stroke; (very rare)

Gut complaints: Nausea; abdominal pain; flatulence (wind); (common). Indigestion; (uncommon). Vomiting; (very rare)

Liver complaints: Gall bladder disease; (uncommon). Liver function changes (e.g. jaundice); (rare)

Skin complaints: Allergic skin reactions (including rash or itching); (uncommon). Skin discolouration; bruise like swellings on the shins; swelling of the throat or face; (very rare)

Muscle and bone: Leg cramps; (common). Back pain; (uncommon)

Reproductive system: Tender breasts; irregular bleeds and spotting; pelvic pain; (common). Vaginal discharge; painful periods; heavy or irregular periods; (uncommon). Swollen breasts; pre-menstrual tension (PMT); (rare)

Inherited conditions: Porphyria (a metabolic disorder) gets worse; (very rare)

General complaints: Asthenia (feeling weak); (common). Fluid retention (i.e. swollen ankles); (uncommon)

Investigations: Weight changes (up or down); (common).

Tumours related to estrogens (both benign and malignant) have been associated with HRT (see ‘Effects on your risk of developing cancer’ above)

An increase in the size of progestagen dependant tumours (e.g. meningioma) has been associated with estrogen/dydrogesterone treatment.

Dementia: HRT will not prevent memory loss. In one study of women who started using combined HRT after the age of 65, a small increase in the risk of dementia was observed.

Usually, side effects are not common and do not usually last long. If any of these side effects do last for a long time or you notice any other side effects and you are worried about them, please contact your doctor or a pharmacist for advice.

You should stop taking Femoston and contact your doctor if:

you develop any of the conditions listed in the ‘Before taking Femoston’ section; or

you develop a blood clot (see ‘Blood clots’); or

you get sudden problems with your vision, severe headaches or migraines (see ‘Stroke’); or

you develop jaundice (yellowing of the skin); or

you become pregnant; or

your blood pressure increases.

How to store your medicine

Do not store above 30°C. Store in the original container in order to protect from light. Do not take the tablets after the expiry date shown on the pack.

Store all medicines where children cannot see or reach them.

Take any unused tablets back to a pharmacy (chemist).

This leaflet was approved in October 2009.

Remember

This medicine is for you. Please do not offer it to your family and friends, even if they have the same symptoms as you.

For more advice about osteoporosis contact the following organisation:

National Osteoporosis Society

PO Box 10

Radstock

Bath

BA3 3YB

Tel.:(01761) 471771

Helpline:0845 450 0230

registered trade mark

1069708

Capzasin-P Cream

Pronunciation: kap-SAY-sin
Generic Name: Capsaicin
Brand Name: Examples include Capzasin-P and Zostrix

Capzasin-P Cream is used for:

Temporary relief of muscle and joint pain associated with arthritis, simple backaches, sprains, strains, and bruises. It may also be used for other conditions as determined by your doctor.

Capzasin-P Cream is a topical analgesic. Exactly how it works is unknown, but it is thought to decrease the amount of a certain substance (substance P) that transmits pain in the body.

Do NOT use Capzasin-P Cream if:

you are allergic to any ingredient in Capzasin-P Cream

Contact your doctor or health care provider right away if any of these apply to you.

Before using Capzasin-P Cream:

Some medical conditions may interact with Capzasin-P Cream. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

if you are pregnant, planning to become pregnant, or are breast-feeding

if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

if you have allergies to medicines, foods, or other substances

if you have an open wound or damaged, broken, or irritated skin

Some MEDICINES MAY INTERACT with Capzasin-P Cream. Because little, if any, of Capzasin-P Cream is absorbed into the blood, the risk of it interacting with another medicine is low.

Ask your health care provider if Capzasin-P Cream may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Capzasin-P Cream:

Use Capzasin-P Cream as directed by your doctor. Check the label on the medicine for exact dosing instructions.

An extra patient leaflet is available with Capzasin-P Cream. Talk to your pharmacist if you have questions about this information.

Apply just enough medicine to cover the affected area. Gently massage the medicine into skin until it disappears.

Wash your hands with soap and water immediately after using Capzasin-P Cream unless your hands are part of the treated area.

If you are using Capzasin-P Cream on your hands, allow 30 minutes for the medicine to absorb before washing. During this time, avoid touching damaged or irritated skin, contact lenses, or your eyes, nose, mouth, or other mucous membranes. Wash hands after 30 minutes.

Do not apply to wounds or damaged, broken (open), or irritated skin.

Do not bandage or wrap the affected area.

Do not use Capzasin-P Cream with a heating pad.

Do not expose the treated area to heat or direct sunlight. Warm or hot water or sunlight may increase the likelihood of burning or itching. Do not use Capzasin-P Cream immediately after bathing, swimming, using a hot tub, sunbathing, or exposure to heat.

If you miss a dose of Capzasin-P Cream, use it as soon as you remember. Continue to use it as directed by your doctor or on the package label.

Ask your health care provider any questions you may have about how to use Capzasin-P Cream.

Important safety information:

For external use only. Avoid contact with the eyes, nose, and mouth. If Capzasin-P Cream gets into your eyes, rinse immediately with cool water.

Do not use more than the recommended dose, use for longer than prescribed, or use large amounts of Capzasin-P Cream without checking with your doctor.

Do not inhale any residue from Capzasin-P Cream after it has dried. Coughing, sneezing, or throat or respiratory irritation may occur.

Capzasin-P Cream may be harmful if swallowed. If you may have taken Capzasin-P Cream by mouth, contact your local poison control center or emergency room immediately.

If condition worsens, or if symptoms persists for more than 7 days or clear up and occur again within a few days, stop use of this product and contact your health care provider.

If redness is present or if irritation develops, check with your doctor before using any more of Capzasin-P Cream.

If severe burning or itching occurs, remove product by thoroughly washing the area with soap and cold water.

Capzasin-P Cream should not be used in CHILDREN younger than 18 years old without checking with the child's doctor; safety and effectiveness in these children have not been confirmed.

PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Capzasin-P Cream while you are pregnant. It is not known if Capzasin-P Cream is found in breast milk. If you are or will be breast-feeding while you use Capzasin-P Cream, check with your doctor. Discuss any possible risks to your baby.

Possible side effects of Capzasin-P Cream:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Temporary burning or stinging at the application site that usually disappears in a few days.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); difficulty breathing or swallowing; irritation, redness, blistering, or severe or persistent burning at the application site.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Capzasin-P side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Capzasin-P Cream may be harmful if swallowed.

Proper storage of Capzasin-P Cream:

Store Capzasin-P Cream at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Close cap tightly after use. Do not store in the bathroom. Keep Capzasin-P Cream out of the reach of children and away from pets.

General information:

If you have any questions about Capzasin-P Cream, please talk with your doctor, pharmacist, or other health care provider.

Capzasin-P Cream is to be used only by the patient for whom it is prescribed. Do not share it with other people.

If your symptoms do not improve or if they become worse, check with your doctor.

Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Capzasin-P Cream. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

More Capzasin-P resources

Capzasin-P Side Effects (in more detail)
Capzasin-P Use in Pregnancy & Breastfeeding
Capzasin-P Drug Interactions
Capzasin-P Support Group
0 Reviews for Capzasin-P - Add your own review/rating

Compare Capzasin-P with other medications

Diabetic Nerve Damage
Osteoarthritis
Pain
Persisting Pain, Shingles

Friday, 7 September 2012

VaZol-D

Generic Name: brompheniramine and phenylephrine (BROM fen IR a meen and FEN il EFF rin)

Brand Names: Alacol, Alenaze-D, Alenaze-D NR, B-Vex D, BPM PE, Brom Tann PE, Bromfed, Bromfed-PD Capsules, BroveX ADT, BroveX PEB, Brovex-D, Children's Cold & Allergy, Dimaphen Elixir, Dimetapp Cold & Allergy, Entre-B, J-Tan D, J-Tan D SR, Phenyl 15/12mg, Phenyl 7.5/6mg, RespaHist II, Rhinabid, Rhinabid PD, Seradex-LA, Tanabid SR, V-Hist, VazoBid, VaZol-D, Vazotab, Zotex-PE

What is VaZol-D (brompheniramine and phenylephrine)?

Brompheniramine is an antihistamine that reduces the natural chemical histamine in the body. Histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose.

Phenylephrine is a decongestant that shrinks blood vessels in the nasal passages. Dilated blood vessels can cause nasal congestion (stuffy nose).

The combination of brompheniramine and phenylephrine is used to treat nasal congestion, sneezing, itching, watery eyes, and runny nose caused by allergies, hay fever, and the common cold.

Brompheniramine and phenylephrine may also be used for purposes not listed in this medication guide.

What is the most important information I should know about VaZol-D (brompheniramine and phenylephrine)?

Do not give this medication to a child younger than 4 years old. Always ask a doctor before giving a cough or cold medicine to a child. Death can occur from the misuse of cough and cold medicines in very young children. You should not use this medication if you are allergic to brompheniramine or phenylephrine, or to other decongestants, diet pills, stimulants, or ADHD medications. Do not use brompheniramine and phenylephrine if you have used an MAO inhibitor such as furazolidone (Furoxone), isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam, Zelapar), or tranylcypromine (Parnate) in the last 14 days. A dangerous drug interaction could occur, leading to serious side effects.

Ask a doctor or pharmacist about taking brompheniramine and phenylephrine if you have heart disease or high blood pressure, diabetes, a thyroid disorder, glaucoma, kidney disease, an enlarged prostate, or problems with urination.

What should I discuss with my healthcare provider before taking VaZol-D (brompheniramine and phenylephrine)?

You should not use this medication if you are allergic to brompheniramine or phenylephrine, or to other decongestants, diet pills, stimulants, or ADHD medications. Do not use brompheniramine and phenylephrine if you have used an MAO inhibitor such as furazolidone (Furoxone), isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam, Zelapar), or tranylcypromine (Parnate) in the last 14 days. A dangerous drug interaction could occur, leading to serious side effects.

Ask a doctor or pharmacist if it is safe for you to take brompheniramine and phenylephrine if you have:

heart disease or high blood pressure;

diabetes;

a thyroid disorder;

glaucoma;

kidney disease;

an enlarged prostate; or

problems with urination.

FDA pregnancy category C. It is not known whether brompheniramine and phenylephrine will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant while using this medication. Brompheniramine and phenylephrine can pass into breast milk and may harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

How should I take VaZol-D (brompheniramine and phenylephrine)?

Use exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended. Cough or cold medicine is usually taken only for a short time until your symptoms clear up.

Do not give this medication to a child younger than 4 years old. Always ask a doctor before giving a cough or cold medicine to a child. Death can occur from the misuse of cough and cold medicines in very young children. Take the medicine with a full glass of water. Do not crush, chew, break, or open an extended-release capsule. Swallow it whole. Breaking or opening the pill may cause too much of the drug to be released at one time.

The chewable tablet must be chewed before you swallow it.

Measure liquid medicine with a special dose-measuring spoon or cup, not a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.

Shake the oral suspension (liquid) well just before you measure a dose. Do not take brompheniramine and phenylephrine for longer than 7 days in a row. Talk with your doctor if your symptoms do not improve after 7 days of treatment, or if you have a fever with a headache, cough, or skin rash. Store at room temperature away from moisture and heat.

What happens if I miss a dose?

Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may include feeling restless or nervous, nausea, vomiting, stomach pain, dizziness, drowsiness, dry mouth, warmth or tingly feeling, or seizure (convulsions).

What should I avoid while taking VaZol-D (brompheniramine and phenylephrine)?

This medication may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert.

Avoid becoming overheated or dehydrated during exercise and in hot weather.

Drinking alcohol can increase certain side effects of brompheniramine and phenylephrine. Ask a doctor or pharmacist before using any other cold, cough, allergy, or pain medicine. Antihistamines and decongestants are contained in many combination medicines. Taking certain products together can cause you to get too much of a certain drug. Check the label to see if a medicine contains an antihistamine or decongestant.

Avoid taking this medication if you also take diet pills, caffeine pills, or other stimulants (such as ADHD medications). Taking a stimulant together with a decongestant can increase your risk of unpleasant side effects.

VaZol-D (brompheniramine and phenylephrine) side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using this medication and call your doctor at once if you have a serious side effect such as:

fast, pounding, or uneven heartbeat;

severe dizziness, anxiety, restless feeling, or nervousness;

easy bruising or bleeding, unusual weakness, fever, chills, body aches, flu symptoms;

nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); or

dangerously high blood pressure (severe headache, blurred vision, buzzing in your ears, anxiety, confusion, chest pain, shortness of breath, uneven heartbeats, seizure).

Less serious side effects may include:

drowsiness or dizziness;

blurred vision;

dry mouth, nose, or throat;

mild stomach pain, constipation;

problems with memory or concentration;

feeling restless or excited (especially in children);

sleep problems (insomnia); or

warmth, redness, or tingly feeling under your skin.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect VaZol-D (brompheniramine and phenylephrine)?

Before using brompheniramine and phenylephrine, tell your doctor if you regularly use other medicines that make you sleepy (such as cold or allergy medicine, sedatives, narcotic pain medicine, sleeping pills, muscle relaxers, and medicine for seizures, depression, or anxiety). They can add to sleepiness caused by brompheniramine and phenylephrine.

Tell your doctor about all other medications you are using, especially:

medicines to treat high blood pressure;

a beta blocker such as atenolol (Tenormin, Tenoretic), carvedilol (Coreg), labetalol (Normodyne, Trandate), metoprolol (Dutoprol, Lopressor, Toprol), nadolol (Corgard), propranolol (Inderal, InnoPran), sotalol (Betapace), and others; or

antidepressants such as amitriptyline (Elavil), clomipramine (Anafranil), imipramine (Janimine, Tofranil), and others.

This list is not complete and other drugs may interact with brompheniramine and phenylephrine. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.

More VaZol-D resources

VaZol-D Side Effects (in more detail)
VaZol-D Use in Pregnancy & Breastfeeding
VaZol-D Drug Interactions
VaZol-D Support Group
0 Reviews for VaZol-D - Add your own review/rating

Alenaze-D Elixir MedFacts Consumer Leaflet (Wolters Kluwer)

Bromfed MedFacts Consumer Leaflet (Wolters Kluwer)

BroveX-D Suspension MedFacts Consumer Leaflet (Wolters Kluwer)

Entre-B Prescribing Information (FDA)

J-Tan D Chewable Tablets MedFacts Consumer Leaflet (Wolters Kluwer)

Rhinabid Sustained-Release Capsules MedFacts Consumer Leaflet (Wolters Kluwer)

Compare VaZol-D with other medications

Hay Fever
Nasal Congestion
Rhinitis

Where can I get more information?

Your pharmacist can provide more information about brompheniramine and phenylephrine.

See also: VaZol-D side effects (in more detail)

Monday, 3 September 2012

Adcal D3 Lemon Chewable Tablets

1. Name Of The Medicinal Product

Adcal-D₃® Lemon Chewable tablets

2. Qualitative And Quantitative Composition

Per tablet:

Calcium carbonate: 1500 mg, equivalent to 600 mg of elemental calcium

Colecalciferol: 400 IU, equivalent to 10 μg vitamin D₃

This product also contains sucrose (part of the vitamin D₃ concentrate: approximately 1.7 milligrams per tablet) and soya oil (also part of the vitamin D₃ concentrate: approximately 0.3 milligrams per tablet).

For full list of excipients see 6.1

3. Pharmaceutical Form

Chewable tablet

4. Clinical Particulars

4.1 Therapeutic Indications

As an adjunct to specific therapy for osteoporosis and in situations requiring therapeutic supplementation of malnutrition e.g. in pregnancy and established vitamin D dependent osteomalacia.

The prevention and treatment of calcium deficiency/vitamin D deficiency especially in the housebound and institutionalised elderly subjects. Deficiency of the active moieties is indicated by raised levels of PTH, lowered 25-hydroxy vitamin D and raised alkaline phosphatase levels which are associated with increased bone loss.

4.2 Posology And Method Of Administration

Oral.

Adults and Elderly and Children above 12 years of age:

2 chewable tablets per day, preferably one tablet each morning and evening.

Children:

Not recommended for children under 12 years.

4.3 Contraindications

Absolute contra-indications are hypercalcaemia resulting for example from myeloma, bone metastases or other malignant bone disease, sarcoidosis; primary hyperparathyroidism and vitamin D overdosage. Severe renal failure. Hypersensitivity to any of the tablet ingredients.

Relative contra-indications are osteoporosis due to prolonged immobilisation, renal stones, severe hypercalciuria.

Adcal-D₃ Lemon contains a small quantity of soya oil and is therefore contraindicated in patients who are allergic to peanuts or soya.

4.4 Special Warnings And Precautions For Use

Patients with mild to moderate renal failure or mild hypercalciuria should be supervised carefully including periodic checks of plasma calcium levels and urinary calcium excretion.

In patients with a history of renal stones urinary calcium excretion should be measured to exclude hypercalciuria.

With long-term treatment it is advisable to monitor serum and urinary calcium levels and kidney function, and reduce or stop treatment temporarily if urinary calcium exceeds 7.5 mmol/24 hours (300 mg/24 hours).

Caution is required in patients receiving treatment for cardiovascular disease (see Section 4.5 – thiazide diuretics and cardiac glycosides including digitalis).

Adcal-D₃ Lemon should also be used with caution in other patients with increased risk of hypercalcaemia e.g. patients with sarcoidosis or those suffering from malignancies.

Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

Each tablet contains a small amount of sugar (about 1.7 mg per tablet) and may be harmful to teeth if used for a prolonged period.

Allowances should be made for calcium and vitamin D supplements from other sources.

4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction

The risk of hypercalcaemia should be considered in patients taking thiazide diuretics since these drugs can reduce urinary calcium excretion. Hypercalcaemia must be avoided in digitalised patients.

Certain foods (e.g. those containing oxalic acid, phosphate or phytinic acid) may reduce the absorption of calcium.

Concomitant treatment with phenytoin or barbiturates can decrease the effect of vitamin D because of metabolic activation. Concomitant use of glucocorticoids can decrease the effect of vitamin D.

The effects of digitalis and other cardiac glycosides may be accentuated with the oral administration of calcium combined with Vitamin D. Strict medical supervision is needed and, if necessary monitoring of ECG and calcium.

Calcium salts may reduce the absorption of thyroxine, bisphosphonates, sodium fluoride, quinolone or tetracycline antibiotics or iron. It is advisable to allow a minimum period of four hours before taking the calcium.

4.6 Pregnancy And Lactation

During pregnancy and lactation treatment with Adcal-D₃ Lemon should always be under the direction of a physician. During pregnancy and lactation, requirements for calcium and vitamin D are increased but in deciding on the required supplementation allowances should be made for availability of these agents from other sources. If Adcal-D₃ Lemon and iron supplements are both required to be administered to the patient, they should be taken at different times (see Section 4.5).

Overdoses of vitamin D have shown teratogenic effects in pregnant animals. However, there have been no studies on the use of this medicinal product in human pregnancy and lactation. In humans, long term hypercalcaemia can lead to physical and mental retardation, aortic stenosis and retinopathy in a new born child. Vitamin D and its metabolites pass into the breast milk.

4.7 Effects On Ability To Drive And Use Machines

None known.

4.8 Undesirable Effects

The use of calcium supplements has, rarely, given rise to mild gastro-intestinal disturbances, such as constipation, flatulence, nausea, gastric pain, diarrhoea. Following administration of vitamin D supplements occasional skin rash has been reported. Hypercalciuria, and in rare cases hypercalcaemia have been seen with long term treatment at high dosages.

4.9 Overdose

The most serious consequence of acute or chronic overdose is hypercalcaemia due to vitamin D toxicity. Symptoms may include nausea, vomiting, polyuria, anorexia, weakness, apathy, thirst and constipation. Chronic overdoses can lead to vascular and organ calcification as a result of hypercalcaemia. Treatment should consist of stopping all intake of calcium and vitamin D and rehydration.

5. Pharmacological Properties

5.1 Pharmacodynamic Properties

Strong evidence that supplemental calcium and vitamin D₃ can reduce the incidence of hip and other non-vertebral fractures derives from an 18 month randomised placebo controlled study in 3270 healthy elderly women living in nursing homes or apartments for elderly people. A positive effect on bone mineral density was also observed.

In patients treated with 1200 mg elemental calcium and 800 IU vitamin D daily, i.e. the same dose delivered by two tablets of Adcal-D₃ Lemon, the number of hip fractures was 43% lower (p = 0.043) and the total number of non vertebral fractures was 32% lower than among those who received placebo. Proximal femur bone mineral density after 18 months of treatment increased 2.7% in the calcium/vitamin D₃ group and decreased 4.6% in the placebo group (p < 0.001). In the calcium/vitamin D₃ group, the mean serum PTH concentration decreased by 44% from baseline at 18 months and serum 25-hydroxy-vitamin D concentration had increased by 162% over baseline.

Analysis of the intention-to-treat results showed a decreased probability of both hip fractures (p = 0.004) and other fractures (p < 0.001) in the calcium/vitamin D₃ treatment group. Analysis of the other two populations (active treatment and those treated and followed for 18 months) revealed comparable results to the intention-to-treat analysis. The odds ratio for hip fractures among women in the placebo group compared with those in the calcium/vitamin D₃ group was 1.7 (95% CI 1.0 to 2.8) and that for other nonvertebral fractures was 1.4 (95% CI 1.4 to 2.1). In the placebo group, there was a marked increase in the incidence of hip fractures over time whereas the incidence in the calcium/vitamin D₃ group was stable. Thus treatment reduced the age-related risk of fracture at 18 months (p = 0.007 for hip fractures and p = 0.009 for all non-vertebral fractures). At 3 years follow-up, the decrease in fracture risk was maintained in the calcium/vitamin D₃ group.

5.2 Pharmacokinetic Properties

The pharmacokinetic profiles of calcium and its salts are well known. Calcium carbonate is converted to calcium chloride by gastric acid. Calcium is absorbed to the extent of about 15-25% from the gastro-intestinal tract while the remainder reverts to insoluble calcium carbonate and calcium stearate, and is excreted in the faeces.

The pharmacokinetics of vitamin D is also well known. Vitamin D is well absorbed from the gastro-intestinal tract in the presence of bile. It is hydroxylated in the liver to form 25-hydroxycholecalciferol and then undergoes further hydroxylation in the kidney to form the active metabolite 1,25-dihydroxycholecalciferol (calcitriol). The metabolites circulate in the blood bound to a specific α–globin, Vitamin D and its metabolites are excreted mainly in the bile and faeces.

5.3 Preclinical Safety Data

Calcium carbonate and vitamin D are well known and widely used materials and have been used in clinical practice for many years. As such toxicity is only likely to occur in chronic overdosage where hypercalcaemia could result.

6. Pharmaceutical Particulars

6.1 List Of Excipients

Xylitol, modified maize starch, sodium saccharin, magnesium stearate, DL-α-tocopherol, edible fats, gelatin, soya oil, sucrose, corn starch and lemon flavour.

6.2 Incompatibilities

Not applicable, oral preparation.

6.3 Shelf Life

18 months.

6.4 Special Precautions For Storage

Do not store above 25^oC.

6.5 Nature And Contents Of Container

Blister packs of 10 (physicians sample), 30, 56, 60, 90, 100 and 112 tablets in a cardboard carton.

6.6 Special Precautions For Disposal And Other Handling

No special conditions.

7. Marketing Authorisation Holder

ProStrakan Limited

Galabank Business Park

Galashiels

TD1 1QH

8. Marketing Authorisation Number(S)

PL 16508/0028

9. Date Of First Authorisation/Renewal Of The Authorisation

19/07/2007

10. Date Of Revision Of The Text

20/05/2009

Thursday, 30 August 2012

Chlorpheniramine/Phenylephrine Chewable Tablets

Pronunciation: KLOR-fen-IR-a-meen/FEN-il-EF-rin
Generic Name: Chlorpheniramine/Phenylephrine
Brand Name: Rynatan

Chlorpheniramine/Phenylephrine Chewable Tablets are used for:

Relieving symptoms of sinus congestion, sinus pressure, runny nose, and sneezing due to colds, upper respiratory tract infections, and allergies. It may also be used for other conditions as determined by your doctor.

Chlorpheniramine/Phenylephrine Chewable Tablets are an antihistamine and decongestant combination. The antihistamine works by blocking the action of histamine, which helps reduce symptoms such as watery eyes and sneezing. The decongestant promotes sinus and nasal drainage, relieving congestion and pressure.

Do NOT use Chlorpheniramine/Phenylephrine Chewable Tablets if:

you are allergic to any ingredient in Chlorpheniramine/Phenylephrine Chewable Tablets

you have severe high blood pressure, severe heart blood vessel disease, rapid heartbeat, or severe heart problems

you are unable to urinate or are having an asthma attack

you take droxidopa, sodium oxybate (GHB), or if you have taken furazolidone or a monoamine oxidase inhibitor (MAOI) (eg, phenelzine) within the last 14 days

Contact your doctor or health care provider right away if any of these apply to you.

Before using Chlorpheniramine/Phenylephrine Chewable Tablets:

Some medical conditions may interact with Chlorpheniramine/Phenylephrine Chewable Tablets. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

if you are pregnant, planning to become pregnant, or are breast-feeding

if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

if you have allergies to medicines, foods, or other substances

if you have a history of adrenal gland problems (eg, adrenal gland tumor); heart problems (eg, cor pulmonale; fast, slow, or irregular heartbeat; heart disease); high blood pressure; diabetes; blood vessel problems; stroke; glaucoma or increased pressure in the eye; seizures; or thyroid problems

if you have a history of asthma or other breathing problems, chronic cough, lung problems (eg, chronic bronchitis, emphysema), chronic obstructive pulmonary disease (COPD), or sleep apnea

if you have a blockage of your bladder, stomach, or bowels; ulcers; trouble sleeping; trouble urinating; an enlarged prostate or other prostate problems

Some MEDICINES MAY INTERACT with Chlorpheniramine/Phenylephrine Chewable Tablets. Tell your health care provider if you are taking any other medicines, especially any of the following:

Digoxin or droxidopa because the risk of irregular heartbeat or heart attack may be increased

Beta-blockers (eg, propranolol), catechol-O-methyltransferase (COMT) inhibitors (eg, tolcapone), furazolidone, linezolid; MAOIs (eg, phenelzine), sodium oxybate (GHB), or tricyclic antidepressants (eg, amitriptyline) because they may increase the risk of Chlorpheniramine/Phenylephrine Chewable Tablets's side effects

Bromocriptine or hydantoins (eg, phenytoin) because the risk of their side effects may be increased by Chlorpheniramine/Phenylephrine Chewable Tablets

Guanadrel, guanethidine, mecamylamine, methyldopa, or reserpine because their effectiveness may be decreased by Chlorpheniramine/Phenylephrine Chewable Tablets

This may not be a complete list of all interactions that may occur. Ask your health care provider if Chlorpheniramine/Phenylephrine Chewable Tablets may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Chlorpheniramine/Phenylephrine Chewable Tablets:

Use Chlorpheniramine/Phenylephrine Chewable Tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Take Chlorpheniramine/Phenylephrine Chewable Tablets by mouth with or without food.

Chew thoroughly before swallowing.

If you miss a dose of Chlorpheniramine/Phenylephrine Chewable Tablets and you are taking it regularly, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Chlorpheniramine/Phenylephrine Chewable Tablets.

Important safety information:

Chlorpheniramine/Phenylephrine Chewable Tablets may cause drowsiness, dizziness, or blurred vision. These effects may be worse if you take it with alcohol or certain medicines. Use Chlorpheniramine/Phenylephrine Chewable Tablets with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.

Do not drink alcohol or use medicines that may cause drowsiness (eg, sleep aids, muscle relaxers) while you are using Chlorpheniramine/Phenylephrine Chewable Tablets; it may add to their effects. Ask your pharmacist if you have questions about which medicines may cause drowsiness.

Do not take diet or appetite control medicines while you are taking Chlorpheniramine/Phenylephrine Chewable Tablets without checking with your doctor.

Before you start any new medicine, check the label to see if it has a decongestant or antihistamine in it too. If it does or if you are not sure, check with your doctor or pharmacist.

Do NOT take more than the recommended dose or take Chlorpheniramine/Phenylephrine Chewable Tablets for longer than prescribed without checking with your doctor.

If your symptoms do not get better within 5 to 7 days or if they get worse, consult your doctor.

Chlorpheniramine/Phenylephrine Chewable Tablets may cause you to become sunburned more easily. Avoid the sun, sunlamps, or tanning booths until you know how you react to Chlorpheniramine/Phenylephrine Chewable Tablets. Use a sunscreen or wear protective clothing if you must be outside for more than a short time.

Chlorpheniramine/Phenylephrine Chewable Tablets may interfere with skin allergy tests. If you are scheduled for a skin test, talk to your doctor. You may need to stop taking Chlorpheniramine/Phenylephrine Chewable Tablets for a few days before the tests.

Tell your doctor or dentist that you take Chlorpheniramine/Phenylephrine Chewable Tablets before you receive any medical or dental care, emergency care, or surgery.

Use Chlorpheniramine/Phenylephrine Chewable Tablets with caution in the ELDERLY; they may be more sensitive to its effects, especially confusion, dizziness, drowsiness, dry mouth, excitability, low blood pressure, and trouble urinating.

Use Chlorpheniramine/Phenylephrine Chewable Tablets with caution in CHILDREN; they may be more sensitive to its effects, especially excitability.

PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Chlorpheniramine/Phenylephrine Chewable Tablets while you are pregnant. It is not known if Chlorpheniramine/Phenylephrine Chewable Tablets are found in breast milk. Do not breast-feed while taking Chlorpheniramine/Phenylephrine Chewable Tablets.

Possible side effects of Chlorpheniramine/Phenylephrine Chewable Tablets:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Constipation; diarrhea; dizziness; drowsiness; dry mouth, nose, or throat; excitability; headache; loss of appetite; nausea; nervousness or anxiety; trouble sleeping; upset stomach; vomiting; weakness.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); blurred vision or other vision changes; confusion; difficulty urinating or inability to urinate; fast or irregular heartbeat; fever, chills, or persistent sore throat; hallucinations; mood or mental changes; persistent trouble sleeping; restlessness; seizures; severe dizziness, drowsiness, lightheadedness, or headache; tremor.

See also: Chlorpheniramine/Phenylephrine side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blurred vision; confusion; hallucinations; ringing in the ears; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; unusually fast, slow, or irregular breathing; unusually fast, slow, or irregular heartbeat; vomiting.

Proper storage of Chlorpheniramine/Phenylephrine Chewable Tablets:

Store Chlorpheniramine/Phenylephrine Chewable Tablets at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Chlorpheniramine/Phenylephrine Chewable Tablets out of the reach of children and away from pets.

General information:

If you have any questions about Chlorpheniramine/Phenylephrine Chewable Tablets, please talk with your doctor, pharmacist, or other health care provider.

Chlorpheniramine/Phenylephrine Chewable Tablets are to be used only by the patient for whom it is prescribed. Do not share it with other people.

If your symptoms do not improve or if they become worse, check with your doctor.

Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Chlorpheniramine/Phenylephrine Chewable Tablets. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

More Chlorpheniramine/Phenylephrine resources

Chlorpheniramine/Phenylephrine Side Effects (in more detail)
Chlorpheniramine/Phenylephrine Dosage
Chlorpheniramine/Phenylephrine Use in Pregnancy & Breastfeeding
Drug Images
Chlorpheniramine/Phenylephrine Drug Interactions
Chlorpheniramine/Phenylephrine Support Group
7 Reviews for Chlorpheniramine/Phenylephrine - Add your own review/rating

Compare Chlorpheniramine/Phenylephrine with other medications

Cold Symptoms
Hay Fever

Sunday, 26 August 2012

Wyeth

Address

Wyeth,
5 Giralda Farms

Madison, New Jersey 07940

Contact Details

Phone: (973) 301-2193
Website: http://www.wyeth.com
Careers: http://www.pfizer.com/careers/
Patient Assistance Program: http://www.wyeth.com/contact?rid=...

Antimetabolites

A drug may be classified by the chemical type of the active ingredient or by the way it is used to treat a particular condition. Each drug can be classified into one or more drug classes.

Antimetabolites are drugs that interfere with one or more enzymes or their reactions that are necessary for DNA synthesis. They affect DNA synthesis by acting as a substitute to the actual metabolites that would be used in the normal metabolism (for example antifolates interfere with the use of folic acid).

Antimetabolites are drugs used in cancer chemotherapy. Cancer cells divide more rapidly compared to normal cells so antimetabolites affect cancer cell replication more than they affect normal cell replication.